WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S246802492402415X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690650803437568 |
|---|---|
| author | Chee Kay Cheung Stephanie Moody Neeraj Dhaun Siân Griffin Alexandra Howson Alex Mercer Matthew Sayer Smeeta Sinha Lisa Willcocks Jonathan Barratt |
| author_facet | Chee Kay Cheung Stephanie Moody Neeraj Dhaun Siân Griffin Alexandra Howson Alex Mercer Matthew Sayer Smeeta Sinha Lisa Willcocks Jonathan Barratt |
| author_sort | Chee Kay Cheung |
| collection | DOAJ |
| format | Article |
| id | doaj-art-a9f6a7788a944e9481f1a908d8a3aa76 |
| institution | DOAJ |
| issn | 2468-0249 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-a9f6a7788a944e9481f1a908d8a3aa762025-08-20T03:21:15ZengElsevierKidney International Reports2468-02492025-02-01102S20410.1016/j.ekir.2024.11.393WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIALChee Kay Cheung0Stephanie Moody1Neeraj Dhaun2Siân Griffin3Alexandra Howson4Alex Mercer5Matthew Sayer6Smeeta Sinha7Lisa Willcocks8Jonathan Barratt9N/A, University of Leicester & Leicester General Hospital, Leicester, United KingdomBiostatistics, Travere Therapeutics, Inc., San Diego, United StatesDepartment of Renal Medicine, Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, United KingdomDepartment of Nephrology and Transplantation, University Hospital of Wales, Cardiff, United KingdomN/A, University of Leicester & Leicester General Hospital, Leicester, United KingdomN/A, JAMCO Pharma Consulting, Stockholm, SwedenDepartment of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, United KingdomSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Department of Renal Medicine, Salford, United KingdomAddenbrooke's Hospital, Cambridge University Hospitals, Department of Renal Medicine, Cambridge, United KingdomDepartment of Nephrology, University of Leicester & Leicester General Hospital, Leicester, United Kingdomhttp://www.sciencedirect.com/science/article/pii/S246802492402415X |
| spellingShingle | Chee Kay Cheung Stephanie Moody Neeraj Dhaun Siân Griffin Alexandra Howson Alex Mercer Matthew Sayer Smeeta Sinha Lisa Willcocks Jonathan Barratt WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL Kidney International Reports |
| title | WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL |
| title_full | WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL |
| title_fullStr | WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL |
| title_full_unstemmed | WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL |
| title_short | WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL |
| title_sort | wcn25 1884 sparsentan spar as first line treatment of incident patients with iga nephropathy igan interim analysis of the spartan trial |
| url | http://www.sciencedirect.com/science/article/pii/S246802492402415X |
| work_keys_str_mv | AT cheekaycheung wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT stephaniemoody wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT neerajdhaun wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT siangriffin wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT alexandrahowson wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT alexmercer wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT matthewsayer wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT smeetasinha wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT lisawillcocks wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial AT jonathanbarratt wcn251884sparsentansparasfirstlinetreatmentofincidentpatientswithiganephropathyiganinterimanalysisofthespartantrial |